Finepoint Capital LP Sells 1,500 Shares of argenx SE (NASDAQ:ARGX)

Finepoint Capital LP lessened its holdings in shares of argenx SE (NASDAQ:ARGX - Free Report) by 2.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 52,928 shares of the company's stock after selling 1,500 shares during the period. argenx comprises 2.0% of Finepoint Capital LP's holdings, making the stock its 4th largest holding. Finepoint Capital LP owned 0.09% of argenx worth $32,551,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in ARGX. Whipplewood Advisors LLC acquired a new stake in argenx during the fourth quarter worth about $37,000. Global Retirement Partners LLC lifted its position in shares of argenx by 369.2% during the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock worth $38,000 after buying an additional 48 shares during the last quarter. Jones Financial Companies Lllp boosted its stake in argenx by 1,016.7% in the fourth quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock valued at $41,000 after buying an additional 61 shares in the last quarter. Whittier Trust Co. of Nevada Inc. grew its position in argenx by 78.6% in the fourth quarter. Whittier Trust Co. of Nevada Inc. now owns 75 shares of the company's stock valued at $46,000 after acquiring an additional 33 shares during the last quarter. Finally, Huntington National Bank raised its stake in argenx by 1,133.3% during the fourth quarter. Huntington National Bank now owns 74 shares of the company's stock worth $46,000 after acquiring an additional 68 shares in the last quarter. 60.32% of the stock is owned by institutional investors.

Remove Ads

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on ARGX shares. Piper Sandler upped their price objective on shares of argenx from $620.00 to $725.00 and gave the stock an "overweight" rating in a research report on Tuesday, January 7th. Truist Financial reissued a "buy" rating and set a $700.00 price objective (up previously from $660.00) on shares of argenx in a report on Tuesday, January 14th. Robert W. Baird upped their target price on argenx from $650.00 to $680.00 and gave the stock a "neutral" rating in a report on Tuesday, March 4th. Wedbush reissued an "outperform" rating and set a $715.00 price target on shares of argenx in a research note on Friday. Finally, Deutsche Bank Aktiengesellschaft raised argenx from a "sell" rating to a "hold" rating in a research note on Wednesday, March 12th. Three analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, argenx currently has a consensus rating of "Moderate Buy" and an average target price of $690.33.

argenx Stock Performance

Shares of NASDAQ ARGX traded up $35.81 during trading on Friday, hitting $582.03. 373,958 shares of the company traded hands, compared to its average volume of 304,649. The business's fifty day moving average is $609.28 and its 200 day moving average is $603.68. The firm has a market capitalization of $35.36 billion, a price-to-earnings ratio of -661.40 and a beta of 0.60. argenx SE has a fifty-two week low of $352.77 and a fifty-two week high of $678.21.

argenx (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.60. The business had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. On average, analysts predict that argenx SE will post 3.13 EPS for the current year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.